Is Testosterone Replacement Therapy in Older Men Effective and Safe?
Is Testosterone Replacement Therapy in Older Men Effective and Safe?
复制标题
DOI：
10.1007/s40266-019-00716-2
复制
发表时间：
2019-11
期刊：
影响因子：
2.8
通讯作者：
Tsitouras PD
中科院分区：
文献类型：
--
作者：
Yabluchanskiy A;Tsitouras PD
到2050年，美国65岁以上老年人的数量预计将增加到近1亿，比目前的4600万增加一倍多。在美国老年人中，高龄与身体虚弱的增加有关，并经常导致残疾、住院、机构化和最终死亡的增加。为了寻找改善与年龄有关的不良健康后果风险的方法，恢复日益减少的性激素的问题引起了人们的极大兴趣，并导致在老年男子中实行性激素替代疗法。最近的数据显示，从2001年到2011年，美国60岁以上男性的雄激素处方率翻了两番。虽然睾丸激素的处方销售额从2000年的1.5亿美元增加到2011年的18亿美元，但很大一部分男性处方睾丸激素替代疗法不符合性腺功能减退的实验室标准。虽然一些临床试验报告了老年男性睾丸激素不足与死亡风险增加之间的关联，但睾丸激素替代疗法的确切效果和后果，特别是对老年男性，仍不清楚。本综述旨在讨论60岁以上老年男性睾酮替代疗法的可能益处和并发症。
The number of older adults over 65 years of age is expected to increase to almost 100 million in the US by 2050, more than double the current figure of 46 million. Advanced age is associated with increased frailty among older Americans and often leads to increased disability, hospitalization, institutionalization, and, eventually, mortality. In search of means to improve age-related risks for adverse health outcomes, the question of restoring diminishing sex hormones has gathered much interest and has led to the practice of sex hormone replacement therapies in older men. Recent data suggest that androgen prescription rates in the US for men older than 60 years of age quadrupled from the years 2001 to 2011. While prescription sales of testosterone have increased from $150 million in 2000 to $1.8 billion in 2011, a significant portion of men prescribed testosterone replacement therapy did not meet the laboratory criteria for hypogonadism. While some clinical trials reported an association between testosterone insufficiency in older men and increased risk of death, the exact effects and consequences of testosterone replacement therapy, specifically in older men, remain unclear. This review is aimed at discussing the possible benefits and complications of testosterone replacement therapy in older men over 60 years of age.
登录
查看更多内容
2001 年至 2011 年美国雄激素处方趋势。
影响因子：
39
作者：
Baillargeon, Jacques;Urban, Randall J.;Ottenbacher, Kenneth J.;Pierson, Karen S.;Goodwin, James S.
通讯作者：
Goodwin, James S.
DOI：
10.1056/nejmoa1000485
发表时间：
2010-07-08
期刊：
The New England journal of medicine
影响因子：
--
作者：
Basaria S;Coviello AD;Travison TG;Storer TW;Farwell WR;Jette AM;Eder R;Tennstedt S;Ulloor J;Zhang A;Choong K;Lakshman KM;Mazer NA;Miciek R;Krasnoff J;Elmi A;Knapp PE;Brooks B;Appleman E;Aggarwal S;Bhasin G;Hede-Brierley L;Bhatia A;Collins L;LeBrasseur N;Fiore LD;Bhasin S
通讯作者：
Bhasin S
影响因子：
3.7
作者：
Finkle WD;Greenland S;Ridgeway GK;Adams JL;Frasco MA;Cook MB;Fraumeni JF Jr;Hoover RN
通讯作者：
Hoover RN
影响因子：
44.5
作者：
Huang, Grace;Wharton, Whitney;Basaria, Shehzad
通讯作者：
Basaria, Shehzad
DOI：
10.1258/136218003100322323
发表时间：
2003-09-01
期刊：
The journal of the British Menopause Society
影响因子：
--
作者：
Almeida, Osvaldo P;Flicker, Leon
通讯作者：
Flicker, Leon